Ipratropiumbromid/Salbutamol Neutec

Ipratropium bromide, the active ingredient in Ipratropiumbromid/Salbutamol Neutec, is a bronchodilator presented as a combination formulation with salbutamol for inhalation use. It works to open narrowed airways, providing relief in chronic obstructive pulmonary disease (COPD) and asthma by reducing bronchoconstriction and improving airflow.

GNH USA supplies Ipratropiumbromid/Salbutamol Neutec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide/Salbutamol is a dual bronchodilator used in respiratory disorders that cause airway narrowing.

COPD: Improves airflow and reduces breathlessness in chronic obstructive pulmonary disease. Asthma: Provides rapid relief of bronchospasm in asthma patients. Acute bronchospasm: Relieves sudden airway constriction during exacerbations.

The medication may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dry mouth or throat irritation - Cough or hoarseness after inhalation - Tremor of the hands or muscles - Headache - Palpitations or mild tachycardia - Nausea

Serious or Rare Side Effects: - Paradoxical bronchospasm (worsening of breathing difficulty) - Severe tachyarrhythmias or cardiac rhythm disturbances - Angioedema or severe allergic reactions - Hyperglycemia, especially in diabetic patients - Hypokalemia (low blood potassium levels)

Before using this inhalation product, consider the following safety measures.

Hypersensitivity: Avoid if the patient has known allergy to ipratropium, salbutamol or any excipients. Cardiovascular disease: Use with caution in patients with arrhythmias, hypertension or coronary artery disease. Diabetes: Monitor blood glucose as salbutamol may raise glucose levels. Pregnancy and lactation: Use only if the potential benefit outweighs the risk; consult a healthcare professional. Store at room temperature: Keep in the original container, protect from moisture and light.

Drug interactions may alter the efficacy or safety of the combination inhaler.

Major Interactions (Avoid): - Non‑selective beta‑blockers: May diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): Potential for exaggerated cardiovascular effects.

Moderate Interactions (Monitor Closely):\n- Theophylline: May increase risk of tachycardia and tremor. - Diabetic medications: Salbutamol can raise blood glucose, requiring dose adjustments. - Systemic corticosteroids: May enhance risk of hypokalemia when used together.